

FOR IMMEDIATE WORLDWIDE RELEASE

For Further Information, Contact:
John J. Millerick
Senior Vice President and CFO
(978) 977-3000

**ANALOGIC CORPORATION ACQUIRES SOUND TECHNOLOGY
TRANSDUCER UNIT FROM SIEMENS MEDICAL SOLUTIONS**

PEABODY, MA (Nov. 7, 2002) – Analogic Corporation (NASDAQ: ALOG) announced today that it has acquired the Siemens-owned Sound Technology transducer unit (often referred to as STI) from Siemens (NYSE: SI) Medical Solutions Ultrasound Division. STI, which employs approximately 110 people at its 27,000 sq. ft. facility in State College, PA, produces linear and tightly curved array ultrasound transducers and probes for a broad range of clinical applications that are supplied to medical equipment companies worldwide.

Bernard Gordon, Chairman of the Board and CEO of Analogic said, “Acquisition of this leading transducer supplier significantly strengthens Analogic’s ability to serve the medical ultrasound market. The acquisition will enable Analogic and STI to pursue new business opportunities with their highly competitive products and to support STI’s current OEM customers.”

“We believe that Analogic will offer Sound Technology and its products additional growth in the OEM market through its proven sales channels,” commented John Pavlidis, president of the Siemens Medical Solutions Ultrasound Division. “We also look forward to a continued relationship with STI as a customer of their exceptional ultrasound transducers.”

STI will remain as a preferred supplier of selected transducers to Siemens and Siemens will continue to deliver parts and products to STI. Siemens reports that the sale of this unit will allow the company to focus on its core competencies from a global perspective.

Terms of the acquisition agreement were not disclosed.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging

Analogic Acquires STI - con't

(MRI), Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing. Analogic is an OEM supplier of advanced ultrasound systems and sub-systems. Its B-K Medical subsidiary, based in Denmark, is the leading supplier of ultrasound systems and transducers primarily for the urology and surgery markets worldwide. For more information on Analogic, visit www.analogic.com.

Siemens Medical Solutions of Siemens AG (NYSE: SI) with headquarters in Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is renowned for its innovative products, including imaging systems for diagnosis, therapy equipment for treatment, hearing instruments, and critical care and life support systems, as well as a wide array of information technology and data management solutions that optimize workflow and increase efficiency in hospitals, clinics and doctors' offices. The company is known as the premiere health information application service provider processing more than 136 million transactions daily and managing more than 86 terabytes of data – twice the information volume of the Library of Congress. Employing approximately 30,000 people worldwide, the company reported sales of 7.2 billion EUR, orders of 8.4 billion EUR and EBITA of 808 million EUR in fiscal 2001 (September, 30). More information can be obtained by visiting us on the Web at www.siemensmedical.com.

This press release contains the Company's or management's intentions, hopes, beliefs, expectations or predictions. These are considered "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements (statements which are not historical facts) in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements, including statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development expenses and trends, and capital expenditures involve risk and uncertainties and actual events and results may differ significantly from those in any forward-looking statements. Actual results may differ materially from those indicated by such statements as a result of various factors, including those discussed in the Company's periodic reports filed with the SEC.

###